GB8804188D0
(en)
*
|
1988-02-23 |
1988-03-23 |
Croda Int Plc |
Pharmaceutical compositions
|
US5407957A
(en)
*
|
1990-02-13 |
1995-04-18 |
Martek Corporation |
Production of docosahexaenoic acid by dinoflagellates
|
DK0457950T3
(da)
*
|
1990-05-23 |
1994-03-07 |
Nestle Sa |
Anvendelse af stearidonsyre til behandling af inflammatorisk betingede sygdomme
|
GB9012651D0
(en)
*
|
1990-06-06 |
1990-07-25 |
Efamol Holdings |
Essential fatty acid treatment
|
WO1992012711A1
(en)
*
|
1991-01-24 |
1992-08-06 |
Martek Corporation |
Microbial oil mixtures and uses thereof
|
ES2136189T3
(es)
*
|
1993-01-15 |
1999-11-16 |
Abbott Lab |
Lipidos estructurados.
|
US20050027004A1
(en)
*
|
1993-06-09 |
2005-02-03 |
Martek Biosciences Corporation |
Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
|
US5411988A
(en)
*
|
1993-10-27 |
1995-05-02 |
Bockow; Barry I. |
Compositions and methods for inhibiting inflammation and adhesion formation
|
US5840715A
(en)
*
|
1995-12-11 |
1998-11-24 |
Inholtra Investment Holdings & Trading, N.V. |
Dietary regimen of nutritional supplements for relief of symptoms of arthritis
|
EP0855908B1
(en)
*
|
1995-12-11 |
2002-02-06 |
Omni Nutraceuticals, Inc. |
Dietary regimen of nutritional supplements for relief of symptoms of arthritis
|
DE19629433A1
(de)
*
|
1996-07-22 |
1998-01-29 |
Hoechst Ag |
Omega-3-fettsäurenenthaltende Zubereitung aus Mikroorganismen als Prophylaktikum bzw. Therapeutikum gegen parasitäre Erkrankungen beim Tier
|
US6075183A
(en)
*
|
1997-04-11 |
2000-06-13 |
Abbott Laboratories |
Methods and compositions for synthesis of long chain poly-unsaturated fatty acids in plants
|
US5972664A
(en)
|
1997-04-11 |
1999-10-26 |
Abbott Laboratories |
Methods and compositions for synthesis of long chain poly-unsaturated fatty acids
|
US5968809A
(en)
*
|
1997-04-11 |
1999-10-19 |
Abbot Laboratories |
Methods and compositions for synthesis of long chain poly-unsaturated fatty acids
|
US7745694B1
(en)
|
1997-04-11 |
2010-06-29 |
Monsanto Technology Llc |
Methods and compositions for synthesis of long chain polyunsaturated fatty acids in plants
|
US6051754A
(en)
*
|
1997-04-11 |
2000-04-18 |
Abbott Laboratories |
Methods and compositions for synthesis of long chain poly-unsaturated fatty acids in plants
|
US6180671B1
(en)
|
1998-03-10 |
2001-01-30 |
Beth Israel Deaconess Medical Center, Inc. |
Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected
|
US6136795A
(en)
*
|
1998-11-18 |
2000-10-24 |
Omni Nutraceuticals, Inc |
Dietary regimen of nutritional supplements for relief of symptoms of arthritis
|
GB9901809D0
(en)
|
1999-01-27 |
1999-03-17 |
Scarista Limited |
Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
|
WO2001051598A1
(en)
|
2000-01-11 |
2001-07-19 |
Monsanto Technology Llc |
Process for making an enriched mixture of polyunsaturated fatty acid esters
|
JP5135568B2
(ja)
*
|
2001-06-18 |
2013-02-06 |
ネプチューン テクノロジーズ アンド バイオリソーシイズ インク |
心臓血管疾患、関節炎、皮膚ガン、糖尿病、月経前症候群および経皮送達の予防および/または治療のためのオキアミおよび/または海洋生物の抽出物
|
WO2004091603A1
(fr)
*
|
2003-04-07 |
2004-10-28 |
Clinigenetics |
Utilisation d’un ester de dha pour le traitement des malades cardiovasculaires
|
US8633247B2
(en)
*
|
2003-08-11 |
2014-01-21 |
Hill's Pet Nutrition, Inc. |
Method for decreasing cartilage damage in dogs
|
US8633246B2
(en)
*
|
2003-08-11 |
2014-01-21 |
Hill's Pet Nutrition, Inc. |
Omega-3 fatty acids for osteoarthritis
|
US8075910B2
(en)
*
|
2004-05-20 |
2011-12-13 |
Pbm Pharmaceuticals, Inc. |
Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions
|
RU2396073C2
(ru)
*
|
2004-11-29 |
2010-08-10 |
Унилевер Нв |
Пероральная композиция для улучшения свойств кожи
|
US20060286199A1
(en)
*
|
2005-06-03 |
2006-12-21 |
Marilou Laprise |
Method and composition for increasing omega-3 lipid in milk
|
ES2391305T3
(es)
*
|
2006-04-12 |
2012-11-23 |
Unilever N.V. |
Composición oral que comprende un ácido graso poliinsaturado y ácido salicílico para obtener un efecto antiinflamatorio en la piel
|
PL2189155T3
(pl)
*
|
2006-04-12 |
2016-07-29 |
Unilever Nv |
Doustna kompozycja o przeciwstarzeniowym działaniu na skórę
|
US20090018186A1
(en)
*
|
2006-09-06 |
2009-01-15 |
The Coca-Cola Company |
Stable beverage products comprising polyunsaturated fatty acid emulsions
|
US20080058418A1
(en)
*
|
2006-09-06 |
2008-03-06 |
The Coca-Cola Company |
Stable polyunsaturated fatty acid emulsions and methods for inhibiting, suppressing, or reducing degradation of polyunsaturated fatty acids in an emulsion
|
DE102007055344A1
(de)
*
|
2007-11-19 |
2009-05-20 |
K. D. Pharma Bexbach Gmbh |
Neue Verwendung von Omega-3-Fettsäure(n)
|
DK2334295T3
(en)
|
2008-09-02 |
2017-10-09 |
Amarin Pharmaceuticals Ie Ltd |
PHARMACEUTICAL COMPOSITION COMPREHENSIVE EICOSAPENTAIC ACID AND NICOTIC ACID AND PROCEDURES FOR USING SAME
|
ES2768091T3
(es)
|
2009-02-10 |
2020-06-19 |
Amarin Pharmaceuticals Ie Ltd |
Uso del éster etílico del ácido eicosapentaenoico para tratar la hipertrigliceridemia
|
NZ595204A
(en)
*
|
2009-03-09 |
2014-11-28 |
Pronova Biopharma Norge As |
Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
|
PL2429317T5
(pl)
|
2009-04-17 |
2019-09-30 |
Natac Pharma, S.L. |
Kompozycje bogate w kwasy tłuszczowe omega 3 z niską zawartością kwasu fitanowego
|
MY198422A
(en)
|
2009-04-29 |
2023-08-29 |
Amarin Pharmaceuticals Ie Ltd |
Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
|
NZ627238A
(en)
|
2009-04-29 |
2016-02-26 |
Amarin Pharmaceuticals Ie Ltd |
Stable pharmaceutical composition comprising ethyl eicosapentaenoate
|
MY172372A
(en)
|
2009-06-15 |
2019-11-21 |
Amarin Pharmaceuticals Ie Ltd |
Compositions and methods for lowering triglycerides
|
RU2758369C2
(ru)
|
2009-09-23 |
2021-10-28 |
Амарин Фармасьютикалз Айрлэнд Лимитед |
Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина, и способы ее применения
|
KR101204748B1
(ko)
*
|
2009-12-17 |
2012-11-26 |
(주) 켐포트 |
고도 불포화 지방산을 고농도로 함유하는 트리글리세라이드 유지의 제조방법
|
WO2011097276A1
(en)
*
|
2010-02-02 |
2011-08-11 |
Martek Biosciences Corporation |
Methods and compositions for treating arthritis with docosahexaenoic acid
|
JP2013537185A
(ja)
*
|
2010-09-08 |
2013-09-30 |
プロノヴァ・バイオファーマ・ノルゲ・アーエス |
遊離酸の形のepaおよびdhaを含む脂肪酸油混合物と界面活性剤とスタチンとを含む組成物
|
US11712429B2
(en)
|
2010-11-29 |
2023-08-01 |
Amarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
US20140127289A1
(en)
|
2010-11-29 |
2014-05-08 |
Armarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
EP2775837A4
(en)
|
2011-11-07 |
2015-10-28 |
Amarin Pharmaceuticals Ie Ltd |
METHODS OF TREATING HYPERTRIGLYCERIDEMIA
|
US11291643B2
(en)
|
2011-11-07 |
2022-04-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
AU2013207368A1
(en)
|
2012-01-06 |
2014-07-24 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
|
ES2685703T3
(es)
|
2012-01-06 |
2018-10-10 |
Omthera Pharmaceuticals Inc. |
Composiciones enriquecidas en DPA de ácidos grasos omega-3 poliinsaturados en forma de ácido libre
|
WO2013169797A1
(en)
|
2012-05-07 |
2013-11-14 |
Omthera Pharmaceuticals, Inc. |
Compositions of statins and omega-3 fatty acids
|
BR112014032905B1
(pt)
|
2012-06-29 |
2022-02-22 |
Amarin Pharmaceuticals Ireland Limited |
Uso de éster etílico do ácido eicosapentaenóico para redução do risco de morte cardiovascular, revascularização coronária e/ou angina instável em um indivíduo em terapia com estatina
|
US20150265566A1
(en)
|
2012-11-06 |
2015-09-24 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
|
US9814733B2
(en)
|
2012-12-31 |
2017-11-14 |
A,arin Pharmaceuticals Ireland Limited |
Compositions comprising EPA and obeticholic acid and methods of use thereof
|
US20140187633A1
(en)
|
2012-12-31 |
2014-07-03 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
|
US9452151B2
(en)
|
2013-02-06 |
2016-09-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing apolipoprotein C-III
|
US9624492B2
(en)
|
2013-02-13 |
2017-04-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
|
US9662307B2
(en)
|
2013-02-19 |
2017-05-30 |
The Regents Of The University Of Colorado |
Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
|
US9283201B2
(en)
|
2013-03-14 |
2016-03-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating or preventing obesity in a subject in need thereof
|
US20140271841A1
(en)
|
2013-03-15 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
|
US10966968B2
(en)
|
2013-06-06 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
|
US20150065572A1
(en)
|
2013-09-04 |
2015-03-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing prostate cancer
|
US9585859B2
(en)
|
2013-10-10 |
2017-03-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
US10561631B2
(en)
|
2014-06-11 |
2020-02-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing RLP-C
|
US10172818B2
(en)
|
2014-06-16 |
2019-01-08 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
US10406130B2
(en)
|
2016-03-15 |
2019-09-10 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
WO2018213663A1
(en)
|
2017-05-19 |
2018-11-22 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject having reduced kidney function
|
US11058661B2
(en)
|
2018-03-02 |
2021-07-13 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
|
AU2019349563B2
(en)
|
2018-09-24 |
2023-06-08 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of cardiovascular events in a subject
|
AU2022263358A1
(en)
|
2021-04-21 |
2023-11-30 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of heart failure
|